{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:24:39Z","timestamp":1790677479087,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008856","name":"Department of Health of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.intimp.2019.105999","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T01:27:29Z","timestamp":1573003649000},"page":"105999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Prognostic and clinicopathological significance of PD-1\/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma"],"prefix":"10.1016","volume":"77","author":[{"given":"Mixue","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.105999_b0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2019.105999_b0010","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2019.105999_b0015","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7\u2013H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2019.105999_b0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2019.105999_b0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2019.105999_b0030","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2019.105999_b0040","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: a new therapeutic paradigm for cancer\u2013preclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.intimp.2019.105999_b0045","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2019.105999_b0050","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2019.105999_b0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2019.105999_b0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2019.105999_b0065","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2019.105999_b0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40364-017-0093-8","article-title":"Utility of PD-L1 immunohistochemistry assays for predicting PD-1\/PD-L1 inhibitor response","volume":"5","author":"Diggs","year":"2017","journal-title":"Biomark. Res."},{"key":"10.1016\/j.intimp.2019.105999_b0075","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2019.105999_b0080","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2019.105999_b0085","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2019.105999_b0090","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2019.105999_b0095","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.intimp.2019.105999_b0100","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","article-title":"Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival","volume":"40","author":"Muenst","year":"2009","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.intimp.2019.105999_b0105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2019.105999_b0110","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.intimp.2019.105999_b0115","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0120","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells","volume":"122","author":"Greaves","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00428-014-1615-5","article-title":"Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma","volume":"465","author":"Ahearne","year":"2014","journal-title":"Virchows Arch."},{"key":"10.1016\/j.intimp.2019.105999_b0130","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/his.12882","article-title":"Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas","volume":"68","author":"Kwon","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.intimp.2019.105999_b0135","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006398","article-title":"The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma","volume":"96","author":"Fang","year":"2017","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.intimp.2019.105999_b0140","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","article-title":"Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma","volume":"20","author":"Smeltzer","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2019.105999_b0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1155\/2010\/404069","article-title":"Diagnostic and prognostic utility of PD-1 in B cell lymphomas","volume":"29","author":"Muenst","year":"2010","journal-title":"Dis. Markers"},{"key":"10.1016\/j.intimp.2019.105999_b0150","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/ejh.12075","article-title":"Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era","volume":"90","author":"Takahashi","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.intimp.2019.105999_b0155","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.humpath.2012.03.025","article-title":"The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease","volume":"43","author":"Koch","year":"2012","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.intimp.2019.105999_b0160","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/jdv.14165","article-title":"Expression of programmed death-1 in cutaneous extranodal natural killer\/T-cell lymphoma and its effect on clinical findings and biological behaviour","volume":"31","author":"Kim","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2019.105999_b0165","article-title":"Programmed cell death 1 and programmed cell death ligands in extranodal natural killer\/T cell lymphoma: expression pattern and potential prognostic relevance","volume":"1\u201311","author":"Muhamad","year":"2019","journal-title":"Acta Haematol."},{"key":"10.1016\/j.intimp.2019.105999_b0170","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00277-016-2818-4","article-title":"Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK\/T-cell lymphoma, nasal type","volume":"96","author":"Jo","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2019.105999_b0175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2019.105999_b0180","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2016-02-698936","article-title":"PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma","volume":"128","author":"Miyoshi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0185","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.58","article-title":"Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression","volume":"4","author":"Oki","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2019.105999_b0190","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0195","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2019.105999_b0200","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/cam4.874","article-title":"PD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma","volume":"5","author":"Zhang","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2019.105999_b0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biopha.2015.08.037","article-title":"Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma","volume":"75","author":"Zhang","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2019.105999_b0210","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000381468","article-title":"Numbers of CD8+PD-1+ and CD4+PD-1+ cells in peripheral blood of patients with chronic lymphocytic leukemia are independent of binet stage and are significantly higher compared to healthy volunteers","volume":"134","author":"Novak","year":"2015","journal-title":"Acta Haematol."},{"key":"10.1016\/j.intimp.2019.105999_b0215","doi-asserted-by":"crossref","first-page":"553","DOI":"10.20452\/pamw.2967","article-title":"Prognostic significance of PD-1 expression on peripheral blood CD4+ T cells in patients with newly diagnosed chronic lymphocytic leukemia","volume":"125","author":"Rusak","year":"2015","journal-title":"Pol. Arch. Med. Wewn."},{"key":"10.1016\/j.intimp.2019.105999_b0220","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/ijc.23042","article-title":"Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia\/lymphoma","volume":"121","author":"Shimauchi","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2019.105999_b0225","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.humpath.2007.11.012","article-title":"Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia","volume":"39","author":"Xerri","year":"2008","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.intimp.2019.105999_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035178","article-title":"Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia","volume":"7","author":"Grzywnowicz","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2019.105999_b0235","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in Sezary syndrome and mycosis fungoides","volume":"148","author":"Cetinozman","year":"2012","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2019.105999_b0240","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/DAD.0b013e3182a72f8c","article-title":"Expression of follicular helper T-cell markers in primary cutaneous T-cell lymphoma","volume":"36","author":"Park","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.intimp.2019.105999_b0245","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.anndiagpath.2017.02.003","article-title":"Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome","volume":"28","author":"Nguyen","year":"2017","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.intimp.2019.105999_b0250","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1097\/PAS.0000000000000694","article-title":"A clinicopathologic study of lennert lymphoma and possible prognostic factors: the importance of follicular helper T-cell markers and the association with angioimmunoblastic T-cell lymphoma","volume":"40","author":"Kurita","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.intimp.2019.105999_b0255","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00277-019-03643-9","article-title":"The correlation of clinicopathological features and prognosis in extranodal natural killer\/T cell lymphoma: a report of 42 cases in the early stage","volume":"98","author":"Zeng","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2019.105999_b0260","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2019.105999_b0265","doi-asserted-by":"crossref","first-page":"709s","DOI":"10.1158\/1078-0432.CCR-06-1868","article-title":"Implications of B7\u2013H1 expression in clear cell carcinoma of the kidney for prognostication and therapy","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2019.105999_b0270","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7\u2013H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2019.105999_b0275","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1593\/neo.05733","article-title":"The B7\u2013H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors","volume":"8","author":"Ghebeh","year":"2006","journal-title":"Neoplasia."},{"key":"10.1016\/j.intimp.2019.105999_b0280","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2019.105999_b0285","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1026530","article-title":"Several immune escape patterns in non-Hodgkin's lymphomas","volume":"4","author":"Laurent","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2019.105999_b0290","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2019.105999_b0295","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0300","doi-asserted-by":"crossref","first-page":"33350","DOI":"10.18632\/oncotarget.9061","article-title":"Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1\/PD-L1 axis activating intracellular AKT\/mTOR pathway in tumor cells","volume":"7","author":"Dong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2019.105999_b0305","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0310","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/ajh.24571","article-title":"CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: possible biomarkers for novel targeted therapies?","volume":"92","author":"Zaja","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2019.105999_b0315","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","article-title":"Identification of a soluble form of B7\u2013H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma","volume":"17","author":"Frigola","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2019.105999_b0320","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2019.105999_b0325","doi-asserted-by":"crossref","first-page":"41228","DOI":"10.18632\/oncotarget.5682","article-title":"Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2019.105999_b0330","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2016.03.002","article-title":"High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis","volume":"59","author":"Finkelmeier","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2019.105999_b0335","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","article-title":"Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy","volume":"66","author":"Nagato","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2019.105999_b0340","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2019.105999_b0345","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/leu.2016.385","article-title":"Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients","volume":"31","author":"Rossille","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2019.105999_b0350","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/hon.2636","article-title":"Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas","volume":"37","author":"Zhang","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.intimp.2019.105999_b0355","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0360","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2019.105999_b0365","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.intimp.2019.105999_b0370","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0375","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0380","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2019.105999_b0385","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2019.105999_b0390","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2005-11-4742","article-title":"Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival","volume":"108","author":"Roberts","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0395","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2019.105999_b0400","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.3109\/10428194.2015.1017820","article-title":"The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia","volume":"56","author":"Grzywnowicz","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.intimp.2019.105999_b0405","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2019.105999_b0410","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study","volume":"2","author":"Keane","year":"2015","journal-title":"Lancet Haematol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919314961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919314961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:15:15Z","timestamp":1761585315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919314961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":81,"alternative-id":["S1567576919314961"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105999","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and clinicopathological significance of PD-1\/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105999","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105999"}}